Lobe Sciences Ltd.
LOBEF · OTC
5/31/2025 | 2/28/2025 | 11/30/2024 | 8/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$2 |
| Operating Expenses | $1 | $1 | $1 | -$2 |
| Operating Income | -$1 | -$1 | -$1 | $2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$5 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$3 |
| % Margin | – | – | – | – |
| EPS | -0.005 | -0.004 | -0.005 | -0.018 |
| % Growth | -34.2% | 24% | 71.9% | – |
| EPS Diluted | -0.005 | -0.004 | -0.005 | -0.018 |
| Weighted Avg Shares Out | 193 | 186 | 159 | 159 |
| Weighted Avg Shares Out Dil | 193 | 186 | 159 | 159 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$3 |
| % Margin | – | – | – | – |